SOURCE: Avadim Technologies Inc.

Avadim Technologies Inc.

November 14, 2016 12:00 ET

Avadim Technologies Inc. Receives Innovative Technology Designation from Vizient, Inc. for Theraworx™ Technology

Designation Recognizes Products That Bring Improvements to the Health Care Industry

ASHEVILLE, NC--(Marketwired - November 14, 2016) - Avadim Technologies Inc., a true "patient first" life sciences company, announced today that its Theraworx™ Technology line of products was awarded with the Innovative Technology designation from Vizient, Inc., the largest member-driven health care performance improvement company in the country. The designation was based on reviews of Theraworx™ by hospital experts who attended Vizient's Innovative Technology Exchange in September 2016. The event provides medical technology suppliers the opportunity to demonstrate their product and gain direct feedback from 1300 onsite clinical experts and health care providers on the impact their products may have on improving clinical care, safety, or benefits to an organization's care and business model.

Theraworx™ Technology is a line of topical therapies that has demonstrated significant benefit to hospitals throughout the country in helping to reduce the incidence of Hospital Acquired Conditions (HAC) in a variety of clinical applications. By creating a low pH acidic environment, Theraworx™ therapies are formulated to restore the skin's immune system and natural function which, when optimized, defend against infection, preserve the skin's permeability barrier and promote skin cohesion and integrity, which dramatically enhances people's lives. The preventative-focused line of products are cost effective, non-caustic, safe and can be used anywhere on the body including mucous membranes.

"To be given an Innovative Technology designation by Vizient member-hospitals provides a strong validation for our company," said Steve Woody, Avadim CEO. "Health systems using our product and protocols are showing incredible progress in HAC prevention with significant CAUTI and UTI reductions. This designation from Vizient is a catalyst for us to bring Theraworx™ to thousands of more hospitals across the country as we continue our mission to serve our customers and help them confront the significant patient care challenges they face on a daily basis. We are gratified and thankful for this opportunity."

"Due to the number of products and services being released and marketed as 'innovative', member hospitals truly value the peer-review system in place at Vizient to help them identify products worth further evaluation at their own facilities," said Debbie Archer, Director of Procurement and leader of Vizient's Innovative Technology program for suppliers. "After a review of Theraworx Technology, Vizient's member council agreed this solution offers unique and incremental benefit over other products available on the market today, and recommended it for an Innovative Technology designation."

Vizient, Inc. represents the combined strengths of the organizations formerly known as VHA Inc., University HealthSystem Consortium, Novation and MedAssets' Spend and Clinical Resource Management. Since 2003, nearly 2200 new and innovative products and technologies have been submitted through the Vizient Innovative Technology program. Vizient works with member-led councils and task forces to identify and review potentially innovative products. If it is determined that a product is innovative, a contract may be awarded outside of Vizient's competitive bid cycle.

Based in Asheville, North Carolina, Avadim Technologies Inc. is the true "patient first" life sciences company. Avadim offers a preventative-focused line of topical therapies that are formulated to restore the skin's immune system and natural function which, when optimized, defend against infection and improve neuromuscular health -- dramatically enhancing people's lives. Avadim believes it's better for humanity to prevent infections than to treat them, thus having a positive benefit on antibiotic stewardship and healthcare costs. For more information, visit

Contact Information